Peanut Allergy Treatment Market Is Expected To Reach $ 992.2 Million By 2030

 San Francisco, 5 Sep 2023: The Report Peanut Allergy Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antihistamines, Epinephrine), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

The global peanut allergy treatment market size is expected to reach USD 992.2 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 10.44% from 2023 to 2030. Some of the key factors propelling the market growth include a robust product pipeline, high disease prevalence, advancement in the drug delivery system, and strategic initiatives by key players.

Key market players are bolstering their pipeline for peanut allergy treatment through various strategies. For instance, Aravax initiated its series B funding round in December 2022, securing a USD 20 million investment from renowned Australian healthcare entrepreneurs Tenmile and Brandon Capital. This financing will enable Aravax to commence phase II clinical trials of PVX108, targeting individuals who experience allergic reactions to peanuts. Such fundings are expected to drive advancements in research and development programs.

The market is stimulated by the increasing number of product approvals for peanut allergy treatment. In January 2020, the U.S. Food and Drug Administration (FDA) granted authorization to PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp], developed by Aimmune Therapeutics, Inc. PALFORZIA is the first immunotherapy medication approved for individuals with peanut allergies. It is an oral immune therapy designed to reduce allergy responses, including anaphylaxis triggered by accidental peanut ingestion. It is intended for individuals who have a confirmed allergy, with initial dose escalation recommended for children aged four to 17.

As of the first quarter of 2023, several promising pipeline products are undergoing clinical development. These include Viaskin Peanut by DBV Technologies, CA002 by Dupixient, and Camallegr, a collaborative effort between Sanofi and Regeneron. Additionally, other assets such as ADP101, VE416, INP20, and CNP-201 are also in development. The introduction of these medications is anticipated to contribute to the growth and expansion of the market during the projected forecast period.

Access Research Report of Peanut Allergy Treatment Market @ https://www.grandviewresearch.com/industry-analysis/peanut-allergy-treatment-market-report

Peanut Allergy Treatment Market Report Highlights

• The epinephrine segment held the major market share in 2022. The standard of care for anaphylaxis treatment has been epinephrine auto-injectors, which are also essential in the management of allergies in emergency situations
• By route of administration, the injectable segment dominated the market in 2022 owing to the development of injectable treatments that are practical, less painful, and easier to use for patients is being pursued in response to the growing emphasis on patient-centered care. This includes looking at alternative delivery systems for injectable therapies, such as wearable technology or auto-injectors
• By distribution channel, the hospital pharmacy segment held the largest market share in 2022. Hospital pharmacies put more of an emphasis on offering patient support and information for people with peanut allergies
• North America has established a strong regional position in the market. This is due to the presence of numerous pharmaceutical companies, academic institutions, and research organizations currently looking into new therapeutic strategies to address the underlying causes of peanut allergies, including gene therapy, biologics, and other immunomodulatory interventions
• A few of the key market players include Sanofi; Aimmune Therapeutics Inc.; DBV Technologies; Vedanta Biosciences, Inc.; Alladapt Immunotherapeutics, Inc.; Regeneron Pharmaceuticals Inc.; Aravax Pty Ltd; Prota Therapeutics; and Teva Pharmaceuticals Industries Ltd.

Peanut Allergy Treatment Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 495.0 million
Revenue forecast in 2030	USD 992.2 million
Growth rate	CAGR of 10.44% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 - 2021
Forecast period	2023 - 2030

List of Key Players in the Peanut Allergy Treatment Market

• Sanofi
• Aimmune Therapeutics Inc.
• DBV Technologies
• Vedanta Biosciences, Inc.
• Alladapt Immunotherapeutics, Inc.
• Regeneron Pharmaceuticals Inc.
• Aravax Pty Ltd
• Prota Therapeutics
• Teva Pharmaceuticals Industries Ltd.

Access Press Release of Peanut Allergy Treatment Market @ https://www.grandviewresearch.com/press-release/global-peanut-allergy-treatment-market